Moderna is counting on its product pipeline to resuscitate its ailing stock - MarketWatch

1. Moderna reported a $1.1 billion loss, exceeding expectations. 2. Revenue dropped to $1.0 billion from $2.8 billion year-over-year. 3. FDA approval timing shifted vaccine sales affecting fourth-quarter performance. 4. Spikevax sales at $923 million still below peak pandemic levels. 5. Guidance for 2025 revenue lowered to $1.5-$2.5 billion, below analyst expectations.